ID Source | ID |
---|---|
PubMed CID | 145813 |
CHEMBL ID | 1651442 |
SCHEMBL ID | 28818 |
MeSH ID | M0249984 |
Synonym |
---|
AC-4409 |
3-nitropyrrole |
FT-0694661 |
lojnbpnackzwai-uhfffaoysa- |
inchi=1/c4h4n2o2/c7-6(8)4-1-2-5-3-4/h1-3,5h |
N0502 |
5930-94-9 |
3-nitro-1h-pyrrole |
A832259 |
beta-nitropyrrole |
CHEMBL1651442 |
ai3-34175 |
1h-pyrrole, 3-nitro- |
AKOS006229842 |
SCHEMBL28818 |
SY004596 |
mfcd00059714 |
3-nitro-1h-pyrole |
3-nitro-1h-pyrrole # |
DTXSID80208042 |
CS-W008547 |
AS-31257 |
AMY14174 |
SB62062 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID566861 | Antibacterial activity against methicillin-resistant Staphylococcus aureus | 2010 | Journal of natural products, Dec-27, Volume: 73, Issue:12 | Nitropyrrolins A-E, cytotoxic farnesyl-α-nitropyrroles from a marine-derived bacterium within the actinomycete family Streptomycetaceae. |
AID566860 | Cytotoxicity against human HCT116 cells | 2010 | Journal of natural products, Dec-27, Volume: 73, Issue:12 | Nitropyrrolins A-E, cytotoxic farnesyl-α-nitropyrroles from a marine-derived bacterium within the actinomycete family Streptomycetaceae. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (41.67) | 18.2507 |
2000's | 6 (50.00) | 29.6817 |
2010's | 1 (8.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.51) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (8.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (91.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |